Regulatory Silence at the FDA

Jordan Paradise

Regulatory Silence at the FDA

Jordan Paradise

Loyola University Chicago, School of Law

Research output: Contribution to journal › Article

Original language	American English
Journal	Minnesota Law Review
Volume	102
Issue number	6
State	Published - 2018

Bibliographical note

Jordan Paradise, Regulatory Silence at the FDA, 102 Minn. L. Rev. 2383 (2018)

Keywords

U.S. Food and Drug Administration (FDA)
risk evaluation and mitigation strategies (REMS)
Biologics Price Competition and Innovation Act (BPCIA)

Disciplines

Administrative Law
Food and Drug Law

Access to Document

Regulatory Silence at the FDAFinal published version, 1.72 MBLicense: Unspecified

Cite this

@article{9f85ea74c4bd412cbb039aa40138c5a9,

title = "Regulatory Silence at the FDA",

keywords = "U.S. Food and Drug Administration (FDA), risk evaluation and mitigation strategies (REMS), Biologics Price Competition and Innovation Act (BPCIA)",

author = "Jordan Paradise",

note = "Jordan Paradise, Regulatory Silence at the FDA, 102 Minn. L. Rev. 2383 (2018)",

year = "2018",

language = "American English",

volume = "102",

journal = "Minnesota Law Review",

number = "6",

}

TY - JOUR

T1 - Regulatory Silence at the FDA

AU - Paradise, Jordan

N1 - Jordan Paradise, Regulatory Silence at the FDA, 102 Minn. L. Rev. 2383 (2018)

PY - 2018

Y1 - 2018

KW - U.S. Food and Drug Administration (FDA)

KW - risk evaluation and mitigation strategies (REMS)

KW - Biologics Price Competition and Innovation Act (BPCIA)

UR - https://lawecommons.luc.edu/facpubs/617

M3 - Article

VL - 102

JO - Minnesota Law Review

JF - Minnesota Law Review

IS - 6

ER -

Regulatory Silence at the FDA

Bibliographical note

Keywords

Disciplines

Access to Document

Other files and links

Cite this